Nipocalimab Can Delay, Prevent Anemia, Intrauterine Transfusion

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Aug. 7, 2024 -- For pregnancies at high risk for early-onset severe hemolytic disease of the fetus and newborn (HDFN), intravenous nipocalimab can delay or prevent fetal anemia or intrauterine transfusions, according to a study published online Aug. 7 in the New England Journal of Medicine.

Kenneth J. Moise Jr., M.D., from Dell Medical School at the University of Texas at Austin, and colleagues examined treatment with intravenous nipocalimab (30 or 45 mg/kg body weight per week) administered from 14 to 35 weeks of gestation in participants with pregnancies at high risk for recurrent early-onset severe HDFN.

The researchers found that seven of 13 pregnancies in the study had live birth at 32 weeks of gestation or later without intrauterine transfusions (54 percent). There were no cases of fetal hydrops; in six cases (46 percent), participants did not receive any antenatal or neonatal transfusions. An intrauterine transfusion was received by six fetuses: five at 24 weeks of gestation or later and one before fetal loss at 22 weeks and five days of gestation. Twelve pregnancies had live births, with a median gestational age at delivery of 36 weeks and four days. One of the 12 live-born infants received one exchange transfusion and one simple transfusion, and five received only simple transfusions. Maternal samples and cord blood had treatment-related decreases in the alloantibody titer and immunoglobulin G level.

"These preliminary efficacy results, together with the preliminary safety data and evidence of the anticipated drug mechanisms, support the further evaluation of nipocalimab in severe HDFN," the authors write.

The study was funded by Janssen Research and Development, which is developing nipocalimab.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-08 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords